Choay, S.a.

Edmond G Vairel

Jean Goulay

Jean Choay

Jean-Claude Lormeau

Francis Toulemonde

Huguette Brouty-Boye

Christian Doutremepuich

The invention relates to a method and composition for thrombolytic treatment. It comprises administering to thrombosis-afflicted patients a low molecular weight heparin in an amount effective to cause lysis of thrombi in vivo.

Method and composition for thrombolytic treatment

The placental pulps notably of human origin are separated from the placental blood, which is removed, and the pulps are macerated in a solution at a pH comprised between 5 and 10, e.g. isotonic NaCl solution, preferably at neutral pH, in the presence of an amino-acid inhibitor of plasminogen activation, at a molar concentration comprised between about 0.001 and 0.1 M, preferably of the order of 0.035 M. The pulps are removed and the solution containing the compounds of the plasminogen type is recovered. Preferred inhibitors are L-lysine, epsilon aminocaproic acid, and trans-4 aminomethyl cyclohexane carboxylic acid.

Compounds of the plasminogen type and method for obtaining such

An initial solution of crude urokinase especially of human origin, is subjected to exclusion chromatography by contact with a DEAE cellulose resin, following adjustment of the pH of the solution to a value of from 4 to 6, and of its conductivity to a value of from 15,000 to 25,000 micromhos. An effluent enriched in urokinase is collected. A urokinase, mixed with foreign proteins, especially pyrogens, is purified by a partial saturation of an aqueous solution of this mixture by ammonium sulphate to a value for which the precipitate formed would not entrain more than 5% of the total activity of urokinase of the initial solution. A supernatant liquid enriched in urokinase is collected . A complex of urokinase and heparin, urokinase heparinate, is made by reacting an enriched solution of urokinase with a solution of heparin. It has relative activities of 30,000 to 100,000 CTA units of urokinase for 100 Iu of heparin. In an isotonic perfusion solution in glucose serum, its dilution is from 300,000 to 900,000 CTA units of urokinase/250 ml.

Purification of urokinase

The present invention relates to pharmaceutical compositions of stable urokinase-heparin complexes, wherein the urokinase is purified, and methods for use thereof.

Growing community of inventors

Paris, France

Edmond G Vairel